Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
June 5, 2013 -- The project will optimize treatment of cancer patients based on the cancers’ individual genetic fingerprint. Intomics will use its leading biomedical data analysis capabilities to help choose the right treatment from cancer-derived genetic information. The project receives €3.0M in financial support from The Danish National Advanced Technology Foundation.
Two cancer patients may respond very differently to the same treatment if their genetic cancer fingerprints differ. Mutations in genes participating in key cancer pathways and mechanisms may impact whether a given patient responds well to a treatment or not. “By enhancing our understanding of the correlation between key mutations in cancer pathways and treatment outcome, we can better select the optimal treatment for each individual patient” says Thomas S. Jensen, CEO of Intomics A/S.
Vejle Sygehus, the Technical University of Denmark (DTU), Exiqon A/S, and Intomics A/S have joined forces to develop a future platform for precision medicine in a five-year project supported by The Danish National Advanced Technology Foundation. The project will focus on colorectal cancer, where genetic information from many samples will be available.
Intomics A/S is developing sophisticated tools for analysing and combining large quantities of biomedical data, including genetic variation data from individuals. Based on these tools and Intomics’ unique expertise within molecular systems biology, genetic data derived from tumours will be analysed and correlated with treatment outcome to advance the field of precision medicine.
Thomas S. Jensen continues, “We are very happy to be part of the project. I see a great synergy between the four partners and strongly believe that by teaming up with leading companies and research institutions in cancer research, data analysis, and diagnostic kit development, we can make important discoveries that can help cancer patients.”
About Intomics
Intomics is a contract research company with leading expertise in biomedical data analysis & data mining, bioinformatics and systems biology. Using pioneering technologies, Intomics provides tailored solutions leading to increased success rates and cost savings in pharmaceutical research projects. For more information, please contact Thomas S. Jensen, CEO, Intomics A/S, p: +45 8880 7979, m: +45 2783 7997 or go to www.intomics.com.
PRFilter
PRFilter is a relevance engine that filters press releases for users based on a personal profile of their interests created from their own, or their publication’s, published articles. The public website also provides anyone with the ability to search thousands of releases from multiple sources or view the most relevant releases in particular areas of interest.
Releases marked with [PRFilter] in the subject line of RealWire release emails indicate PRFilter determined the release passed an individuals relevance threshold. Users can login and increase or decrease this threshold. Users can also train PRFilter to determine release relevance more accurately by providing feedback – “More”, this release is relevant or “Less”, this release is not relevant.
Please visit PRFilter to log in or contact RealWire for more information.
News Receiver Options
Receivers members area – the receivers members area allows you to amend your news category options and preferences, and access your own personal RSS feed of relevant news. Log in now or request log in details.
Unsubscribe – should you wish to unsubscribe from RealWire’s distribution, please click here. We would very much value your feedback on why you wish to be removed in order for us to continue to improve and develop our service.
Disclaimer:
Whilst RealWire Limited endeavour to ensure the accuracy of the information contained in this Release, RealWire Limited cannot accept any liability for:-
• the inaccuracy or otherwise of any information contained in this Release; or
• any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release; or
• any loss or suffering which may be caused by or to any party either as a result of the information contained in this Release or such information contained in this Release being inaccurate or otherwise misleading.
In the event that any information contained in this Release is inaccurate or misleading then please contact RealWire.
RealWire’s privacy policy is available on our website.
RealWire:
The registered address of RealWire is:
Realwire Limited, Unit 1, Exchange Close, North Hykeham, Lincoln, LN6 3TR.
Realwire Limited is a company registered in England and Wales: 4026690
Help employers find you! Check out all the jobs and post your resume.
